Advanced Search

Submit Online

Letters to the Editor

< Previous         Next >  
Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer Free
Yan-Sheng Liu1,†, Xiao-Yang Luo2,3,†, Qing-Run Li1, Hong Li1, Chen Li1, Hong Ni1, Rong-Xia Li1, Rui Wang2,3, Hai-chuan Hu2,3, Yun-jian Pan2,3, Hai-Quan Chen2,3,*, and Rong Zeng1,*
1Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
2Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China *Correspondence to:Rong Zeng, E-mail: zr@sibs.ac.cn; Hai-Quan Chen, E-mail: chenhq@shca.org.cn
J Mol Cell Biol, Volume 4, Issue 5, October 2012, 344-347,  https://doi.org/10.1093/jmcb/mjs050

Lung cancer—predominantly non-small cell lung cancer (NSCLC)—is the most prevalent cancer in the world, in terms of both incidence and mortality. Squamous cell lung cancer (SCLC) is the second most common type of NSCLC, making up about 30% of all cases. The average 5-year survival rate among NSCLC patients is barely 15% (Herbst et al., 2008). Among post-surgery patients, prognosis varies widely, even among patients with similar clinicopathological characteristics, demonstrating the need for improved ways to predict treatment outcomes (Chen et al., 2007).

Volume 4, Issue 5
October 2012